2021-25111. Discovery Therapeutics, LLC, et al.; Withdrawal of Approval of 18 Abbreviated New Drug Applications  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The Food and Drug Administration (FDA or Agency) is withdrawing approval of 18 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

    DATES:

    Approval is withdrawn as of December 20, 2021.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 240-402-6980, Martha.Nguyen@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.

    Application No.DrugApplicant
    ANDA 040619Methimazole Tablets, 15 milligrams (mg)Discovery Therapeutics, LLC, 2831 Deer Hound Way, Palm Harbor, FL 34683.
    ANDA 070254Naloxone Hydrochloride (HCl) Injection, 0.4 mg/milliliters (mL)Hospira, Inc., 275 North Field Dr., Building H1, Lake Forest, IL 60045.
    ANDA 070586Bupivacaine HCl Injection, 0.25%Do.
    ANDA 071850Morphine Sulfate Injection, 1 mg/mLDo.
    ANDA 075220Desmopressin Acetate Injection, 0.004 mg/mLDo.
    ANDA 076498Tretinoin Cream, 0.05%ZO Skin Health, Inc., 9685 Research Dr., Irvine, CA 92618.
    ANDA 077245Ciprofloxacin Injection, 200 mg/20 mL (10 mg/mL) and 400 mg/40 mL (10 mg/mL)Hospira, Inc.
    ANDA 080409Lidocaine HCl Solution, 4%Do.
    ANDA 087446Chloroprocaine HCl Injection, 3%Do.
    ANDA 087447Chloroprocaine HCl Injection, 2%Do.
    ANDA 201653Levocetirizine Dihydrochloride Tablets, 5 mgSun Pharmaceutical Industries, Inc., U.S. Agent for Sun Pharmaceutical Industries Ltd., 270 Prospect Plains Rd., Cranbury, NJ 08512.
    ANDA 202524Levetiracetam Extended Release Tablets, 500 mg and 750 mgRouses Point Pharmaceuticals, LLC, 11 Commerce Dr., Cranford, NJ 07016.
    ANDA 202857Daptomycin Powder for Injection, 500 mg/vialHospira, Inc.
    ANDA 203885Amiodarone HCl Injection, 50 mg/mLDo.
    ANDA 207864Eptifibatide Injection, 2 mg/mL and 75 mg/100 mLThe WhiteOak Group, LLC, U.S. Agent for Hybio Pharmaceutical Co., Ltd., 1629 K St. NW, Suite 300, Washington, DC 20006.
    ANDA 209489Caspofungin Acetate Powder for Injection, 50 mg/vial and 70 mg/vialCipla USA, Inc., U.S. Agent for Cipla Limited, 10 Independence Blvd., Suite 300, Warren, NJ 07059.
    ANDA 210283Clofarabine Injection, 20 mg/20 mL (1 mg/mL)Hospira, Inc.
    ANDA 210855Sodium Nitroprusside Injection, 25 mg/mLCipla USA, Inc.

    Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of December 20, 2021. Approval of each entire application is withdrawn, including any strengths and dosage forms inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on December 20, 2021 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.

    Start Signature

    Dated: November 12, 2021.

    Lauren K. Roth,

    Associate Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. 2021-25111 Filed 11-17-21; 8:45 am]

    BILLING CODE 4164-01-P

Document Information

Published:
11/18/2021
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
2021-25111
Dates:
Approval is withdrawn as of December 20, 2021.
Pages:
64506-64506 (1 pages)
Docket Numbers:
Docket No. FDA-2021-N-1195
PDF File:
2021-25111.pdf
Supporting Documents:
» Discovery Therapeutics, LLC, et al.; Withdrawal of Approval of 18 Abbreviated New Drug Applications